US FDA approves BridgeBio's drug for rare heart condition

Published on 22 Nov 2024 on Reuters

The oral drug, branded as Attruby, was approved to treat adult patients with transthyretin amyloid...

Read the rest of the article

Start tracking your investments with Statfolio

We recently compiled a list of the 10 High Growth Healthcare Stocks to Invest in Now. In this...

Insider Monkey · via Yahoo Finance 2 Dec 2024

Looking at individual holdings, Applovin Corp (APP) accounts for about 3.20% of total assets,...

Zacks · via Yahoo Finance 29 Nov 2024

The SPDR S&P Biotech ETF (XBI) is an exchange-traded fund that tracks the biotechnology segment o...

The Forex Market 27 Nov 2024

BBIO gets a significant boost with the FDA approval of acoramidis for the treatment of adults wit...

Zacks · via Yahoo Finance 26 Nov 2024

Alnylam Pharmaceuticals, Inc. Price and Consensus Alnylam Pharmaceuticals, Inc....

Zacks · via Yahoo Finance 26 Nov 2024

The United States market has shown robust performance, climbing by 2.2% over the past week with a...

Simply Wall St. · via Yahoo Finance 25 Nov 2024

(Bloomberg) -- BridgeBio Pharma Inc. jumped the most in 16 months after its drug got US regulator...

Bloomberg · via Yahoo Finance 25 Nov 2024

The oral drug, branded as Attruby, was approved to treat adult patients with transthyretin amyloi...

Reuters 22 Nov 2024

Most ETFs are very transparent products...ETF has heaviest allocation in the Healthcare...

Zacks · via Yahoo Finance 20 Nov 2024

Alnylam Pharmaceuticals Inc (ALNY) reports impressive 34% year-over-year revenue growth, advances...

GuruFocus.com · via Yahoo Finance 31 Oct 2024